Colorectal cancer prevention in ulcerative colitis: A case-control study

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 2, 2000, Pages 145-153

  Eaden, J ^a   Abrams, K ^b   Ekbom, A ^c   Jackson, E ^a   Mayberry, J ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; CORTICOSTEROID; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0033980980     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00698.x     Document Type: Article

References (42)

1. 1 Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterology 1988; 94: 1089-91.
2. 2 Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33.
3. 3 Bargen JA, Gage RP. Carcinoma and ulcerative colitis: prognosis. Gastroenterology 1960; 39: 385-93.
4. 4 Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29: 206-17.
5. 5 Katzka I, Brody RS, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis: experience from a private practice. Gastroenterology 1983; 85: 22-9.
6. 6. Lennard-Jones JE, Morson BC, Ritchie JK, Williams CB. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 1983; ii: 149-52.
7. 7 Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988; 94: 870-7.
8. 8 Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979; 77: 290-4.
9. 9 Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH Jr, Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991; 32: 167-9.
10. 10 Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331-8.
11. 11 Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis. A risk factor for the development of dysplasia and DNA aneuploidy. Gastroenterology 1992; 102: 1877-80.
12. 12 Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41: 522-5.
13. 13 Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: A case-control study. Gastroenterology 1998; 115: 1079-83.
14. 14 Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 1989; 97: 255-9.
15. 15 Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994; 107: 117-20.
16. 16 Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Braezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32.
17. 17 Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Halle R. Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 1993; 85: 912-15.
18. 18 Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiology. Biomarkers & Prevention 1995; 4: 703-7.
19. 19 Thun MJ, Namboodira MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
20. 20 Bansal P, Sonnenberg A. Risk factors for colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44-8.
21. 21 Moody GA, Jayanthi V, Probert CSJ, Mackay H, Mayberry JF. Long term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83.
22. 22 Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999; 13: 1397-1402.
23. 23 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24: 2-15.
24. 24 Probert CSJ, Jayanthi V, Pinder D, Wicks AC, Mayberry JF. An epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire, 1972-89. Gut 1992; 33: 687-93.
25. 25 Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
26. 26 Logan RFA, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 1993; 307: 285-9.
27. 27 Giardiello FM, Hamilton SR, Krush AJ. et al. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-16.
28. 28 Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exper Rheumatol 1996; 14: 551-3.
29. 29 Barnes CJ, Cameron IL, Hardman WE, Lee M. Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 1998; 77: 573-80.
30. 30 Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer 1992; 66: 777-80.
31. 31 Choi PM, Nugent FW, Schoetz DJ. Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-24.
32. 32 Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-14.
33. 33 Catnach SM, Rutter KRP, Bown RL. Colorectal carcinoma in patients with ulcerative colitis and recent colonoscopy. Gut 1993; 34: 1148-9.
34. 34 Lennard-Jones JE. Compliance, cost and common sense limit cancer control in colitis. Gut 1986; 27: 1403-7.
35. 35 Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1669-74.
36. 36 Kochhar R, Goenka MK, Kaushik SP, Gupta NM, Nagi B, Mehta SK. Colorectal carcinoma in Indian patients with idiopathic ulcerative colitis. Eur J Cancer Prev 1992; 1: 293-6.
37. 37 Probert CSJ, Jayanthi V, Bhakta P, Wicks ACB, Mayberry JF. How necessary is colectomy? An epidemiological study of the surgical management of ulcerative colitis amongst different ethnic groups in Leicestershire. Eur J Gastroenterol Hepatol 1993; 5: 17-20.
38. 38 Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet 1978; i: 1140-3.
39. 39 Sinclair TS, Brunt PW, Mowat NAG. Nonspecific proctocolitis in Northeastern Scotland: A community study. Gastroenterology 1983; 85: 1-11.
40. 40 Axon ATR. Cancer surveillance in ulcerative colitis - a time for reappraisal. Gut 1994; 35: 587-9.
41. 41 Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia and surveillance in patients with ulcerative colitis: a critical review. N Engl J Med 1987; 316: 1654-8.
42. 42 Gyde S. Screening for colorectal cancer is ulcerative colitis: dubious benefits and high costs. Gut 1990; 31: 1089-92.